Bioventus (NASDAQ:BVS) Trading Down 8.2% – Should You Sell?

Bioventus Inc. (NASDAQ:BVS) fell 8.2% during mid-day trading on Friday . The company traded as low as $8.32 and last traded at $8.35. 154,082 shares changed hands during mid-day trading, a decline of 43% from the average session volume of 272,240 shares. The stock had previously closed at $9.10.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on BVS shares. Barrington Research upgraded Bioventus to a “strong-buy” rating in a report on Monday, February 9th. Weiss Ratings reissued a “hold (c-)” rating on shares of Bioventus in a research report on Monday, December 29th. Finally, Cantor Fitzgerald raised shares of Bioventus to a “strong-buy” rating in a research report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy”.

Bioventus Stock Performance

The business’s 50-day moving average price is $8.10 and its 200-day moving average price is $7.49. The company has a current ratio of 1.74, a quick ratio of 1.14 and a debt-to-equity ratio of 1.50. The stock has a market cap of $693.53 million, a PE ratio of 69.84 and a beta of 0.78.

Bioventus (NASDAQ:BVS) last announced its quarterly earnings data on Thursday, March 5th. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.22 by $0.02. The firm had revenue of $157.90 million during the quarter. Bioventus had a net margin of 1.39% and a return on equity of 26.38%.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.